Highlights ■ Men with metastatic prostate cancer in the public system have access to fewer treatment lines. ■ Survival in the public system was 3 years shorter than that in the private setting (78 versus 115 months). ABSTRACT Objective: To evaluate the impact of assistance from public and private health systems on the overall survival of patients with metastatic prostate cancer. Methods: A total of 213 patients with metastatic prostate cancer treated at the A.C. Camargo Cancer Center, either in […]
